ArticleJournal of ultrasound2025
First-trimester screening for preeclampsia between 11 and 13 + 6 weeks of gestation and adverse perinatal outcomes.
Article in Journal of ultrasound, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Control of HELLP syndrome and pre-eclampsia with microbiota.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the impact of first-trimester screening for preeclampsia (PE) and its association with adverse perinatal outcomes.
methodsA retrospective cohort study was conducted in women with (Group I) or without (Group II) first-trimester screening for PE between 11 and 13 + 6 weeks using maternal characteristics, mean arterial pressure, and uterine artery Doppler. Women were classified as low and high risk using a cut-off value of 1:150 according to the Fetal Medicine Foundation guidelines.
resultsA total of 2442 pregnant women were analysed, 988 in Group I and 1434 in Group II, of whom 204 were at high risk and 1230 at low risk for PE. Group II had higher maternal age (28.0 vs. 26.0 years, p < 0.001), Apgar score at the 1st minute (9.0 vs. 8.0, p < 0.001), Apgar score at the 5th minute (9.0 vs. 8.0, p < 0.001) and lower gestational age at delivery (39.1 vs. 39.4 weeks, p < 0.001) than Group I. Group II was found to have a lower risk of gestational hypertension (p < 0.001), higher risk of delivery < 34 weeks (p = 0.06), and lower risk of spontaneous delivery < 37 weeks (p < 0.001). Women at high risk of PE had a higher risk of delivery < 34 weeks (6.9% vs. 1.2%, p < 0.001), delivery < 37 weeks (16.7% vs. 8.0%, p < 0.001), PE < 34 weeks (2.9% vs. 0.5%, p = 0.005), PE < 37 weeks (4.9% vs. 1.0%, p = 0.0007) and PE > 37 weeks (2.9% vs. 0.5%, p = 0.005). Among women at high risk of PE, 61.3% (125/204) used aspirin (ASA) 100 mg by 37 weeks' gestation. The ASA use was associated with a lower risk of PE > 37 weeks' gestation (0.8% vs. 6.3%, p = 0.033).
conclusionFirst-trimester screening for PE did not reduce the risk of preterm or term PE. First-trimester screening was associated with a lower risk of gestational hypertension and preterm PE. High risk pregnancies had a higher risk of preterm and term PE and of preterm and term delivery. ASA use was associated with lower risk of term PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.